The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Takeda
Stock and Other Ownership Interests - Takeda
Research Funding - Takeda
TAK-676 in combination with pembrolizumab after radiation therapy in patients (pts) with advanced non–small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN): Phase 1 study design.
 
Benjamin T. Cooper
Honoraria - AstraZeneca
 
Steven J. Chmura
Employment - Astellas Pharma (I)
Honoraria - Reflexion Medical
Consulting or Advisory Role - AstraZeneca; Genentech
Research Funding - AstraZeneca/MedImmune; BMS; Merck
Patents, Royalties, Other Intellectual Property - UptoDate article
 
Jason J. Luke
Stock and Other Ownership Interests - Actym Therapeutics; Alphamab; Arch Oncology; Kanaph Therapeutics; Mavu Pharmaceutical; NeoTX; NeoTX; Onc.AI; Pyxis; STipe Therapeutics; Tempest Therapeutics
Consulting or Advisory Role - 7 Hills Pharma; Abbvie; Alnylam; Alphamab; Astellas Pharma; Bayer; Bright Peak Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Codiak Biosciences; Crown Bioscience; CStone Pharmaceuticals; Day One Therapeutics; Eisai; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Genentech; Gilead Sciences; Hotspot Therapeutics; Immunocore; Incyte; Inzen Therapeutics; Janssen; Kadmon; KSQ Therapeutics; Merck; Mersana; Nektar; Novartis; Onc.AI; Partner Therapeutics; Pfizer; Reflexion Medical; Regeneron; Ribon Therapeutics; Rubius Therapeutics; SERVIER; Silicon Therapeutics; Spring Bank; STINGthera; STipe Therapeutics; Synlogic; Synthekine; Tempest Therapeutics; Tesaro; TRex Bio; Werewolf Therapeutics; Xencor; Xilio Therapeutics
Research Funding - Abbvie (Inst); Agios (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); EMD Serono (Inst); Fstar (Inst); Genmab (Inst); Ikena Oncology (Inst); Immatics (Inst); Incyte (Inst); Kadmon (Inst); KAHR Medical (Inst); Macrogenics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Nektar (Inst); NextCure (Inst); Numab (Inst); Replimune (Inst); Rubius Therapeutics (Inst); Scholar Rock (Inst); Spring bank (Inst); Synlogic (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Trishula Therapeutics (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Janssen; Merck; Mersana; Novartis; Pyxis; Reflexion Medical; Xilio Therapeutics
 
Stephen Lawrence Shiao
Consulting or Advisory Role - OncoPep
Research Funding - Merck (Inst); Pinnacle Biologics (Inst)
 
Reva K Basho
Employment - Alignment Healthcare (I)
Stock and Other Ownership Interests - Alignment Healthcare (I)
Consulting or Advisory Role - AstraZeneca; AstraZeneca; bioTheranostics; Pfizer; Seagen
Speakers' Bureau - Seagen
Research Funding - Ichnos Sciences (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst); Takeda (Inst)
Other Relationship - MJH Healthcare Holdings, LLC
(OPTIONAL) Uncompensated Relationships - Novartis
 
Wade Thomas Iams
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb/Pfizer; Chardan Consulting; Curio Science; Defined Health; G1 Therapeutics; Janssen; Jazz Pharmaceuticals; Mirati Therapeutics; Outcomes Insights; Takeda
 
David B. Page
Consulting or Advisory Role - Biotheranostics; Brooklyn ImmunoTherapeutics; Genentech; Lilly; Merck; Novartis; Puma Biotechnology; Sanofi; WindMIL
Speakers' Bureau - Genentech; Novartis
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Brooklyn ImmunoTherapeutics; Brooklyn ImmunoTherapeutics (Inst); Merck; Merck (Inst); WindMIL; WindMIL (Inst)
Expert Testimony - Vincent Davey Law Firm
 
Cong Li
Employment - Takeda
Stock and Other Ownership Interests - Takeda
Patents, Royalties, Other Intellectual Property - Takeda
 
Richard C. Gregory
Employment - Takeda
Stock and Other Ownership Interests - Takeda
Research Funding - Takeda
Travel, Accommodations, Expenses - Takeda
 
Michael Shaw
Employment - Takeda
Stock and Other Ownership Interests - Takeda
Patents, Royalties, Other Intellectual Property - Takeda
 
Kristin Horn
Employment - Takeda
Stock and Other Ownership Interests - Bristol-Myers Squibb; Takeda
 
John Gibbs
Employment - Takeda
Stock and Other Ownership Interests - Takeda
 
Vicky A. Appleman
Employment - Takeda
Stock and Other Ownership Interests - Takeda
Research Funding - Takeda
Patents, Royalties, Other Intellectual Property - Takeda
Travel, Accommodations, Expenses - Takeda
 
Allison J. Berger
Employment - Takeda
Stock and Other Ownership Interests - Takeda
 
Adnan Abu-Yousif
Employment - Takeda
Stock and Other Ownership Interests - Takeda
Research Funding - Takeda
 
Neil Lineberry
Employment - Takeda
Patents, Royalties, Other Intellectual Property - Takeda
Travel, Accommodations, Expenses - Takeda
 
Kate Stumpo
Employment - Takeda
Stock and Other Ownership Interests - AstraZeneca; Bristol-Myers Squibb (I); GlaxoSmithKline (I); Pfizer (I); Takeda; Teva
 
Aymen Elfiky
No Relationships to Disclose
 
Naamit Kurshan Gerber
Honoraria - Group Dynamics In Focus
Consulting or Advisory Role - Invus